Nadine Sauvé

Nadine Sauvé

Auto-generated profile, based on publicly available information

Nadine Sauvé

University of Sherbrooke

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
MGMarie-Eve Gingras-Charland
Marie-Eve Gingras-Charland
ACAnne-Marie Côté
Anne-Marie Côté
PGPascale Girard
Pascale Girard
AGAriane Grenier
Ariane Grenier
JPJean-Charles Pasquier
Jean-Charles Pasquier
NSNadine Sauvé
Nadine Sauvé

6 July 2020 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
GCGabrielle Md Côté-Poirier
Gabrielle Md Côté-Poirier
NBNazila Md Bettache
Nazila Md Bettache
ACAnne-Marie Md Côté
Anne-Marie Md Côté
MMMichèle Md Mahone
Michèle Md Mahone
FMFrancine Morin
Francine Morin
NSNadine Md Sauvé
Nadine Md Sauvé
OBJECTIVE: To evaluate complications associated with early postpartum therapeutic anticoagulation. METHODS: A multicenter retrospective cohort study was done to evaluate the association between therapeutic anticoagulation postpartum and major complications (hemorrhagic and wound complications). Secondary outcomes included minor complications, risk factors associated with total complications (including the time to therapeutic anticoagulation resumption after delivery) and recurrent thrombotic events within 6 weeks postpartum. RESULTS: From 2003 to 2015, 232 consecutive women were treated with therapeutic anticoagulation within 96 hours postpartum; among those treated, 91 received unfractionated heparin, 138 received low-molecular-weight heparin, and three received other anticoagulants. The primary outcome, a composite of major hemorrhagic complications (requiring transfusion, hospitalization, volume resuscitation, transfer to intensive care unit, or surgery) and major wound complications, occurred in 7 of 83 (8.4%) for cesarean deliveries and 9 of 149 (6.0%) for vaginal deliveries (P=.490). Total complications (including major and minor hemorrhagic and wound complications) occurred in 13 of 83 (15.7%) for cesarean deliveries compared with 9 of 149 (6.0%) for vaginal deliveries (P=.016). When comparing cases associated with and without complications, the median delay before resuming anticoagulation was significantly shorter for both cesarean (12 vs 33 hours, P=.033) and vaginal deliveries (6 vs 19 hours, P=.006). For vaginal deliveries, 8 of 51 (15.7%) women had complications when anticoagulation was started before 9.25 hours postpartum, compared with 1 of 98 (1.0%) when started after 9.25 hours. For cesarean deliveries, 7 of 21 (33.3%) of women experienced complications compared with 6 of 62 (9.7%) if anticoagulation was started before or after 15.1 hours, respectively. Two (0.9%) episodes of venous thromboembolism occurred within 6 weeks postpartum. CONCLUSION: Among postpartum women who received early therapeutic anticoagulation, major complications occurred in 8.4% for cesarean deliveries and 6.0% for vaginal deliveries. Complications were associated with earlier resumption of therapeutic anticoagulation, particularly before 9.25 hours for vaginal deliveries and before 15.1 hours for cesarean deliveries.

1 September 2008 in Obstetric Medicine
Verified
Journal Article
Closed access
NSNadine Sauvé
Nadine Sauvé
RPRaymond O Powrie
Raymond O Powrie
LLLucia Larson
Lucia Larson
MPMaureen G Phipps
Maureen G Phipps
SWSherry Weitzen
Sherry Weitzen
KRKaren Rosene-Montella
Karen Rosene-Montella
Objective: This study was undertaken to evaluate whether or not an educational pamphlet could improve knowledge without increasing anxiety in women with preeclampsia. Methods: One hundred women recruited from an inpatient setting with suspected or proven preeclampsia were asked to answer a questionnaire assessing demographics, knowledge (primary outcome), anxiety and satisfaction (secondary outcomes) after being randomized to an intervention group (who received a pamphlet) or a control group (who did not received a pamphlet). The pamphlet and questionnaire, both designed by a multidisciplinary team, were read and answered at the same time. Results: Baseline and demographic characteristics were similar between the two groups. Knowledge about the symptoms of pre-eclampsia was excellent in both groups (61% to 100% correct answers). Women in both groups were well aware that preeclampsia in the past ( P = 0.22) and a family history of preeclampsia ( P = 0.57) were risk factors. There was a significant difference in knowledge about the risk of some fetal complications, including death (90% versus 39%, P < 0.01) and all maternal complications ( P < 0.05) favouring the intervention group. Despite increased knowledge about preeclampsia and its risks, anxiety was not greater in the intervention group. Overall, there was a trend towards less knowledge in vulnerable subgroups (non-white, low income and schooling levels), but the improvement of knowledge with the pamphlet was equivalent. Baseline anxiety was higher in the vulnerable groups, but was generally not increased by the pamphlet. Conclusion: An educational pamphlet for women with suspected preeclampsia was able to increase knowledge without increasing anxiety.

8 April 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MWMarijke Allain Wouterlood
Marijke Allain Wouterlood
IMIsabelle Malhamé
Isabelle Malhamé
KLKateri Lévesque
Kateri Lévesque
NDNatalie Dayan
Natalie Dayan
MMMichèle Mahone
Michèle Mahone
NSNadine Sauvé
Nadine Sauvé

10 February 2022 in Obstetric Medicine
Verified
Journal Article
Closed access
ALAlexia Tanguay Lecomte
Alexia Tanguay Lecomte
LVLauriane Vittoz
Lauriane Vittoz
NSNadine Sauvé
Nadine Sauvé
MRMarie-Ève Roy-Lacroix
Marie-Ève Roy-Lacroix
MMMandy Malick
Mandy Malick
ACAnne-Marie Côté
Anne-Marie Côté
Introduction: Postpartum hypertensive disorders of pregnancy occur in 2-5% of pregnancies. It is a major cause of urgent postpartum consultation and is associated with life-threatening complications. Our objective was to evaluate if local management of postpartum hypertensive disorders of pregnancy was congruent with expert recommendations. Methods: We conducted a quality improvement initiative through a retrospective single-centre cross-sectional study. All women over 18-year-old consulting emergently for hypertensive disorders of pregnancy in the first six weeks postpartum, from 2015 to 2020, were eligible. Results: We included 224 women. Optimal management of postpartum hypertensive disorders of pregnancy was observed in 65.0%. While diagnosis and laboratory work-up were excellent, adequate blood pressure surveillance and recommendations upon discharge of an outpatient postpartum episode (69.7%) did not meet expectations. Conclusion: Efforts should be targeted to improve discharge recommendations on optimal blood pressure surveillance after delivery for women at risk for hypertensive disorders of pregnancy and for postpartum hypertensive disorders of pregnancy in women treated as outpatients.

15 January 2014 in Obstetric Medicine
Verified
Journal Article
Closed access
PGPascale Girard
Pascale Girard
AQAlexandre Quirion
Alexandre Quirion
YBYves-André Bureau
Yves-André Bureau
NSNadine Sauvé
Nadine Sauvé
Background: The current Canadian guidelines endorse the use of MgSO4 for treatment of eclampsia and for prophylaxis in severe preeclampsia. Our study aimed to audit our institution’s compliance regarding these guidelines. Methods: We conducted a retrospective study to evaluate MgSO4 use in: all our cases of eclampsia since 2002, 50 cases of severe preeclampsia, and 50 cases of non-severe preeclampsia. Results: Sixty-five cases of preeclampsia were analyzed after initial chart review. A high rate of preeclampsia severity misdiagnosis was observed (35%, 23/65). Only 69% (25/36) of the patients correctly diagnosed with severe preeclampsia received MgSO4; after diagnosis correction, 42% (25/59) of the patients with severe preeclampsia received the medication. Of our eight cases of eclampsia, none of the patients received MgSO4 before the seizure (although three had clear indications). Conclusion: Given the importance of prophylactic MgSO4 use in preventing eclampsia, we have implemented informative measures aimed at rapidly achieving complete compliance with the national guidelines.